Skip to content
lsd.com

Indication

Opioid Use Disorder

17 registered trials testing LSD, Psilocybin, MDMA, Ketamine, DMT, Ibogaine for this indication, 9 recruiting now.

Sponsors register this under 3 different names, all collected here: Opioid Use Disorder · Opioid Use Disorder (OUD) · Opioid-use Disorder

17
Registered trials
9
Recruiting
0
In Phase 3

Substances tested

Being studied with

Stay told

When a new trial opens

Research alerts

Get a notification when a trial for Opioid Use Disorder trials starts recruiting

This registry is rebuilt every day. If no trial is recruiting for you today, that can change within weeks.

This form sends your email address and the topic of this page to Brevo, our email provider, which stores them on servers in the European Union. We never sell that address, never share it with anyone, and never use it for advertising. One email deletes it. What is held, and where.

Trials

All 17 trials for Opioid Use Disorder

TrialStatusPhaseSubstanceSites
Outpatient Buprenorphine Induction With Psilocybin for Opioid Use DisorderNCT06067737 · Johns Hopkins UniversityRecruitingPhase 2psilocybin1
Psilocybin on Brain Mechanisms of Motivation in OUDNCT06810310 · University of PennsylvaniaRecruitingPhase 2psilocybin1
MDMA for Co-occurring PTSD and OUD After ChildbirthNCT05219175 · University of New MexicoRecruitingPhase 2mdma1
Ketamine for Opioid Use DisorderNCT06943859 · University of Maryland, BaltimoreRecruitingPhase 2ketamine1
Psilocybin for Opioid Use Disorder (OUD)NCT06796062 · NYU Langone HealthRecruitingPhase 2psilocybin5
Wellcome Leap Psilocybin for OUDNCT06786325 · Anna Rose Childress, Ph.D.RecruitingPhase 2psilocybin1
Adjunctive Effects of Psilocybin and a Formulation of BuprenorphineNCT04161066 · University of Wisconsin, MadisonRecruitingPhase 1psilocybin1
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)NCT06160284 · Yale UniversityRecruitingPhase 1psilocybin1
Mapping Ibogaine Neural Dynamics in Opioid Use DisorderNCT07226570 · University of California, IrvineRecruitingN/Aibogaine1
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use DisorderNCT06005662 · Johns Hopkins UniversityWithdrawnPhase 2psilocybin1
Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery EnhancementNCT07369089 · University of California, San DiegoNot yet recruitingPhase 2ketamine2
Ketamine for OUD and Suicidal Ideation in the EDNCT06111339 · Brigham and Women's HospitalTerminatedPhase 2ketamine1
Ketamine for the Treatment of Opioid Use Disorder and DepressionNCT04177706 · Medical University of South CarolinaCompletedPhase 2ketamine1
Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid UseNCT05242029 · Johns Hopkins UniversityWithdrawnPhase 2psilocybin—
Ketamine for OUD and Comorbid Depression (OUDCD)NCT05051449 · University of Maryland, BaltimoreTerminatedPhase 1ketamine1
Transition From Acute to Chronic Opioid Use and Chronic PainNCT07211399 · Jacques E. ChellyWithdrawnEarly Phase 1ketamine1
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic PsychedelicsNCT06624137 · Yale UniversityTerminatedN/Alsd, psilocybin, dmt2

Records from ClinicalTrials.gov API v2, data build 2026-08-25. Indications are the sponsors’ own words. LSD.com reports registered clinical research. It is not medical advice, it is not a recommendation to take any substance, and trial listings are not endorsements. Talk to a clinician.